BUPE for Recovery Act

Strategic National Stockpile. Essential Medicines Strategic Stockpile Act (H.R.405). Prescription Information Modernization Act (H.R.1503/S.2916). Drug Shortages Pandemic and All Hazards Preparedness Reauthorization and Response Act (legislation). Drug Supply Chain Security Act Implementation (DSCSA). Rolling Active Pharmaceutical Ingredient and Drug (RAPID) Reserve Act (S.2510/H.R.6802). SUPPORT Act Reauthorization (S.2433/H.R.4531). FY2025 National Defense Authorization Act. House E&C Drug Shortages Discussion Draft. FY 2024 Continuing Resolution. Seniors Access to Critical Medications Act of 2023 (H.R. 5526/S.3458) Department of Defense Essential Medicines Strategic Stockpile Amendment to NDAA Health Care Cybersecurity Improvement Act of 2024 (S.4054) Broadening Utilization of Proven and Effective Treatment for Recovery Act or the BUPE for Recovery Act (H.R.9886/S.5271)

Client expense: $1,100,000 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Science & Technology Policy (OSTP), SENATE, White House Office

CDC Funding in FY 2025 Labor, Health and Human Services bill, including immunization, smoking and health, social determinants of health, injury and violence prevention, public health preparedness, epi and lab capacity, Data Modernization, Center for Forecasting Outbreak and Analytics, overdose prevention, public health workforce, capacity and infrastructure, infectious diseases Overdose prevention, Modernizing Opioid Treatment Access Act (H.R. 1359/S. 644) Regulation of Tobacco/Nicotine and flavors Extension of federal flexibilities for teleprescribing of controlled substances H.R. 6663/S. 3364, Kid Providing Resources for Optimal Outcomes Against Fatalities (Kid PROOF) Act Reauthorization of the Pandemic and All-Hazards Preparedness Act H.R. 9886/S. 5271, Broadening Utilization of Proven and Effective Treatment for Recovery Act H.R. 10126/S. 5326 Public Health Funding Restoration Act

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 824 - Telehealth Benefit Expansion for Workers Act of 2023 H.R. 1202 / S. 704 - Resident Education Deferred Interest (REDI) Act H.R. 2389 - Resident Physician Shortage Reduction Act of 2023 H.R. 2400 / S. 1165 - Reentry Act of 2023 H.R. 2474 - Strengthening Medicare for Patients and Providers Act H.R. 3073 / S. 1452 - Community Mental Wellness and Resilience Act H.R. 3432 / S. 3651 - Telemental Health Care Access Act of 2023 H.R. 3946/S. 1800 - FASD Respect Act H.R. 4189 / S. 2016 - CONNECT for Health Act of 2023 H.R. 4892 / S. 3921 - Medicaid Bump Act H.R. 4933 / S. 462 - Mental Health Professionals Workforce Shortage Loan Repayment Act H.R. 4942 / S. 665 - Conrad State 30 and Physician Access Reauthorization Act H.R. 5116 / S. 2688 - Behavioral Health Information Technology (BHIT) Coordination Act H.R. 5819 / S. 1378 - COMPLETE Care Act H.R. 6683 - Preserving Seniors Access to Physicians Act of 2023 H.R. 7153 / S. 3679 - Dr. Lorna Breen Health Care Provider Protections Reauthorization Act H.R. 3305 / S. 1606 - Black Maternal Health Momnibus Act H.R. 3226 / S. 1573 - Prematurity Research Expansion and Education for Mothers who deliver Infants Early (PREEMIE) Reauthorization Act of 2023 H.R. 3312 / S. 1602 - Moms Matter Act H.R. 3838 / S. 2415 - Preventing Maternal Deaths Reauthorization Act of 2023 H.R. 7024 - Tax Relief for American Families and Workers Act of 2024 H.R. 8458 / S. 669- Increasing Mental Health Options Act of 2024 H.R. 8543 / S. 2993 - To amend the Social Security Act and the Public Health Service Act to permanently authorize certified community behavioral health clinics, and for other purposes H.R. 8680 - To authorize the Secretary of Health and Human Services, acting through the Assistant Secretary for Mental Health and Substance Use, to award grants to train community mental wellness workers H.R. 8702/ S .4532 - To amend title XVIII of the Social Security Act to establish requirements with respect to the use of prior authorization under Medicare Advantage plans H.R.8767 - To amend title XIX of the Social Security Act to remove the exclusion from medical assistance under the Medicaid program of items and services for patients in an institution for mental diseases S. 1339 - Pharmacy Benefit Reform Manager Act H.R. 7891 / S. 1409 - Kids Online Safety Act H.R. 7890 / S. 1418 - Children and Teens Online Privacy Protection Act (COPPA 2.0) H.R. 4531 / S. 3106 - SUPPORT for Patients and Communities Reauthorization Act H.R. 6663 / S. 3364 - Kid PROOF Act of 2023 S. 3430 - Better Mental Health Care, Lower-Cost Drugs, and Health Extenders Act S. 3157 - More Behavioral Health Providers Act of 2023 H.R. 7619 / S. 3158 - Expand the Behavioral Health Workforce Now Act H.R.6928 - CONNECT Act of 2024 H.R.6961 / S. 3010 - Nutrition CARE Act of 2024 H.R. 6982 / S. 3579 - Gambling Addiction, Recovery, Investment, and Treatment Act H.R. 7050 - Substance Use Disorder Workforce Act of 2024 H.Res. 1089 / S.Res.567 - Health Workforce Well-being Day of Awareness Resolution S. 2556 - Improving Coordination and Access to Resources Equitably (CARE) for Youth Act H.R. 5408 / S. 2767 - SSI Savings Penalty Elimination Act H.R.7301 - Certified Community Behavioral Health Clinic Expansion Act of 2024 H.R. 7808 - EARLY Minds Act H.R. 7265 / S. 3779 - Child Suicide Prevention and Lethal Means Act S. 3638 - Dependent Controlled Substance Transparency Act H.R. 7265 / S. 3379 Child Suicide Prevention & Lethal Means Safety Act H.R.7708 - To amend title XVIII of the Social Security Act to require MA organizations offering network-based plans to maintain an accurate provider directory, and for other purposes H.R.8575 - Michelle Alyssa Go Act H.R. 7258 / S. 3968 - A bill to amend the Public Health Service Act to provide community-based training opportunities for medical students in rural areas and medically under-served communities, and for other purposes S.4023 - Behavioral Health Network and Directory Improvement Act S.4358 - Preventing and Treating Substance Use Disorders Among Older Adults Act Sent letter to the FDA on reducing the scope of the Clozapine REMS in preparation for the Joint Committees Meeting Meeting with FDA on continued Stimulant Shortage APA met with DOL, HHS, and Treasury to Discuss Parity APA sent letter to ONC on Health Data, Technology, and Interoperability: Patient Engagement, Information Sharing, and Public Health Interoperability (HTI-2) proposed rule Signed onto AMA letter on Medicare physician payment reform S.4935- Physician Fee Stabilization Act H.R. 6371 - the Provider Reimbursement Stability Act H.R. 2474 - Strengthening Medicare for Patients and Providers Act H.R. 5013 / S. 3503 - Value in Health Care (VALUE) Act H.R. 1770 / S. 2477 - Equitable Community Access to Pharmacist Services Act. Signed AMA letter in opposition H.R.6664 / S. 4905- Innovation in Pediatric Drugs Act of 2023 H.R.9133 / S. 4835- The Primary and Behavioral Health Care Access Act H.R. 2630 / S. 652 - the Safe Step Act H.R. 9581 - STAR Plus Scholarship Act H.R. 8715 - NEST Act H.R. 9577- Stabilization to Prevent (STOP) Suicide Act H.R. 9656 - Career and Technical Education (CTE) Student Mental Health and Wellness Act S. 5146- Medical Graduate Investment Act of 2024 H.R. 9688 - Keep Kids Covered Act H.R. 9886/S.5271 - Broadening Utilization of Proven and Effective Treatment for Recovery Act H.R. 7858 - Telehealth Enhancement for Mental Health Act of 2024 Cover Our Care Act H.R. 3503 - NIH Clinical Trial Diversity Act of 2023 H.R. 9422 - Recovery Act H.R. 10073 - Medicare Patient Access and Practice Stabilization Act of 2024 H.R. 9457 - Transparent Telehealth Bills Act of 2024 H.R. 3838/S. 2415 - Preventing Maternal Deaths Reauthorization Act of 2023 S.5524 - Parity Enforcement Act of 2024 H.R. 10085 - Saving Lives on Campuses Act of 2024 H.R. 10280 - Strengthening Pathways to Health Professions Act

Fentanyl analogues scheduling extension H.R. 2584-Safety from Violence for Healthcare Employees (SAVE) Act, to establish federal criminal penalties for violence against health care workers H.R. 9886-Broadening Utilization of Proven and Effective Treatment for Recovery Act, to temporarily exempt buprenorphine from the Suspicious Orders Report System for the remainder of the opioid public health emergency S.1080-Cooper Davis Act S.2484-Expanding Nationwide Access to Test Strips Act, to ensure states do not prohibit individuals from possessing or obtaining fentanyl test strips S.2644-American Law Enforcement SAVER Act, to provide standards for trauma kits purchased using Byrne JAG grant funds S.2768-Safety from Violence for Healthcare Employees (SAVE) Act, to establish federal criminal penalties for violence against health care workers S. 5271-Broadening Utilization of Proven and Effective Treatment for Recovery Act, to temporarily exempt buprenorphine from the Suspicious Orders Report System for the remainder of the opioid public health emergency

Client expense: $407,855 · Firm income: Not reported

Advocated for increased FY25 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY25 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for passage of H.R. 7050 - the Substance Use Disorder Workforce Act of 2024, with a recommendation that the Senate include additional monetary incentives in the bill for physicians training as addiction specialists. Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for the Residential Recovery for Seniors Act (H.R. 9232 / S. 4860). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for various substance use disorder workforce and coverage policy changes, including the SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. Supported the Medicaid Bump Act of 2024 (H.R. 4892/S. 3921). This legislation would incentivize states to expand coverage of mental health and substance use disorder (MH/SUD) services by providing a corresponding increase in the Federal Medical Assistance Percentage (FMAP) matching rate to 90 percent. Supported calls for the Biden Administration to rescind a $75 'cap' per patient per budget year on incentives in contingency management for treating stimulant use disorder. Advocated for the finalization of a DOJ/DEA rule to preserve the COVID 19 telemedicine initiation flexibilities for buprenorphine for OUD. Worked on and supported HR 9886/S 5271, the Broadening Utilization of Proven and Effective Treatment for Recovery Act or the BUPE for Recovery Act, which would require the Administrator of the Drug Enforcement Administration (DEA) to temporarily exempt buprenorphine from the Suspicious Orders Report System (SORS) for the remainder of the opioid public health emergency. Joined coalition letter urging passage of the Connecting Our Medical Providers with Links to Expand Tailored and Effective (COMPLETE) Care Act (H.R. 5819/S.1378), which would encourage the adoption of integrated delivery models that will make behavioral health services more accessible to patients. It would do this through a temporary increase in Medicare reimbursement rates for integrated care codes. ASAM joined over 60 organization signatories in a letter to the Centers for Medicare and Medicaid Services (CMS) regarding proposed guidance and templates for parity compliance in Medicaid and the Children's Health Insurance Program (CHIP). Joined coalition letter encouraging CMS to strengthen the Medicaid parity regulations by aligning them with parity regulations recently finalized for commercial plans. The letter also recommended that CMS amend the templates and guidance documents to more closely align with the federal parity statute and regulations. Joined coalition letter requesting that Congress pass legislation to both prevent the scheduled 2.83 percent Medicare physician payment cut and, critically, provide a positive payment update for 2025.

Advocated for increased FY25 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY25 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for passage of H.R. 7050 - the Substance Use Disorder Workforce Act of 2024, with a recommendation that the Senate include additional monetary incentives in the bill for physicians training as addiction specialists. Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for the Residential Recovery for Seniors Act (H.R. 9232 / S. 4860). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for various substance use disorder workforce and coverage policy changes, including the SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. Supported the Medicaid Bump Act of 2024 (H.R. 4892/S. 3921). This legislation would incentivize states to expand coverage of mental health and substance use disorder (MH/SUD) services by providing a corresponding increase in the Federal Medical Assistance Percentage (FMAP) matching rate to 90 percent. Supported calls for the Biden Administration to rescind a $75 'cap' per patient per budget year on incentives in contingency management for treating stimulant use disorder. Advocated for the finalization of a DOJ/DEA rule to preserve the COVID 19 telemedicine initiation flexibilities for buprenorphine for OUD. Worked on and supported HR 9886/S 5271, the Broadening Utilization of Proven and Effective Treatment for Recovery Act or the BUPE for Recovery Act, which would require the Administrator of the Drug Enforcement Administration (DEA) to temporarily exempt buprenorphine from the Suspicious Orders Report System (SORS) for the remainder of the opioid public health emergency. Joined coalition letter urging passage of the Connecting Our Medical Providers with Links to Expand Tailored and Effective (COMPLETE) Care Act (H.R. 5819/S.1378), which would encourage the adoption of integrated delivery models that will make behavioral health services more accessible to patients. It would do this through a temporary increase in Medicare reimbursement rates for integrated care codes. ASAM joined over 60 organization signatories in a letter to the Centers for Medicare and Medicaid Services (CMS) regarding proposed guidance and templates for parity compliance in Medicaid and the Children's Health Insurance Program (CHIP). Joined coalition letter encouraging CMS to strengthen the Medicaid parity regulations by aligning them with parity regulations recently finalized for commercial plans. The letter also recommended that CMS amend the templates and guidance documents to more closely align with the federal parity statute and regulations. Joined coalition letter requesting that Congress pass legislation to both prevent the scheduled 2.83 percent Medicare physician payment cut and, critically, provide a positive payment update for 2025.

Advocated for increased FY25 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY25 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for passage of H.R. 7050 - the Substance Use Disorder Workforce Act of 2024, with a recommendation that the Senate include additional monetary incentives in the bill for physicians training as addiction specialists. Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for the Residential Recovery for Seniors Act (H.R. 9232 / S. 4860). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for various substance use disorder workforce and coverage policy changes, including the SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. Supported the Medicaid Bump Act of 2024 (H.R. 4892/S. 3921). This legislation would incentivize states to expand coverage of mental health and substance use disorder (MH/SUD) services by providing a corresponding increase in the Federal Medical Assistance Percentage (FMAP) matching rate to 90 percent. Supported calls for the Biden Administration to rescind a $75 'cap' per patient per budget year on incentives in contingency management for treating stimulant use disorder. Advocated for the finalization of a DOJ/DEA rule to preserve the COVID 19 telemedicine initiation flexibilities for buprenorphine for OUD. Worked on and supported HR 9886/S 5271, the Broadening Utilization of Proven and Effective Treatment for Recovery Act or the BUPE for Recovery Act, which would require the Administrator of the Drug Enforcement Administration (DEA) to temporarily exempt buprenorphine from the Suspicious Orders Report System (SORS) for the remainder of the opioid public health emergency. Joined coalition letter urging passage of the Connecting Our Medical Providers with Links to Expand Tailored and Effective (COMPLETE) Care Act (H.R. 5819/S.1378), which would encourage the adoption of integrated delivery models that will make behavioral health services more accessible to patients. It would do this through a temporary increase in Medicare reimbursement rates for integrated care codes. ASAM joined over 60 organization signatories in a letter to the Centers for Medicare and Medicaid Services (CMS) regarding proposed guidance and templates for parity compliance in Medicaid and the Children's Health Insurance Program (CHIP). Joined coalition letter encouraging CMS to strengthen the Medicaid parity regulations by aligning them with parity regulations recently finalized for commercial plans. The letter also recommended that CMS amend the templates and guidance documents to more closely align with the federal parity statute and regulations. Joined coalition letter requesting that Congress pass legislation to both prevent the scheduled 2.83 percent Medicare physician payment cut and, critically, provide a positive payment update for 2025.

Advocated for increased FY25 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY25 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for passage of H.R. 7050 - the Substance Use Disorder Workforce Act of 2024, with a recommendation that the Senate include additional monetary incentives in the bill for physicians training as addiction specialists. Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for the Residential Recovery for Seniors Act (H.R. 9232 / S. 4860). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for various substance use disorder workforce and coverage policy changes, including the SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. Supported the Medicaid Bump Act of 2024 (H.R. 4892/S. 3921). This legislation would incentivize states to expand coverage of mental health and substance use disorder (MH/SUD) services by providing a corresponding increase in the Federal Medical Assistance Percentage (FMAP) matching rate to 90 percent. Supported calls for the Biden Administration to rescind a $75 'cap' per patient per budget year on incentives in contingency management for treating stimulant use disorder. Advocated for the finalization of a DOJ/DEA rule to preserve the COVID 19 telemedicine initiation flexibilities for buprenorphine for OUD. Worked on and supported HR 9886/S 5271, the Broadening Utilization of Proven and Effective Treatment for Recovery Act or the BUPE for Recovery Act, which would require the Administrator of the Drug Enforcement Administration (DEA) to temporarily exempt buprenorphine from the Suspicious Orders Report System (SORS) for the remainder of the opioid public health emergency. Joined coalition letter urging passage of the Connecting Our Medical Providers with Links to Expand Tailored and Effective (COMPLETE) Care Act (H.R. 5819/S.1378), which would encourage the adoption of integrated delivery models that will make behavioral health services more accessible to patients. It would do this through a temporary increase in Medicare reimbursement rates for integrated care codes. ASAM joined over 60 organization signatories in a letter to the Centers for Medicare and Medicaid Services (CMS) regarding proposed guidance and templates for parity compliance in Medicaid and the Children's Health Insurance Program (CHIP). Joined coalition letter encouraging CMS to strengthen the Medicaid parity regulations by aligning them with parity regulations recently finalized for commercial plans. The letter also recommended that CMS amend the templates and guidance documents to more closely align with the federal parity statute and regulations. Joined coalition letter requesting that Congress pass legislation to both prevent the scheduled 2.83 percent Medicare physician payment cut and, critically, provide a positive payment update for 2025.

Advocated for increased FY25 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY25 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for passage of H.R. 7050 - the Substance Use Disorder Workforce Act of 2024, with a recommendation that the Senate include additional monetary incentives in the bill for physicians training as addiction specialists. Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for the Residential Recovery for Seniors Act (H.R. 9232 / S. 4860). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for various substance use disorder workforce and coverage policy changes, including the SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. Supported the Medicaid Bump Act of 2024 (H.R. 4892/S. 3921). This legislation would incentivize states to expand coverage of mental health and substance use disorder (MH/SUD) services by providing a corresponding increase in the Federal Medical Assistance Percentage (FMAP) matching rate to 90 percent. Supported calls for the Biden Administration to rescind a $75 'cap' per patient per budget year on incentives in contingency management for treating stimulant use disorder. Advocated for the finalization of a DOJ/DEA rule to preserve the COVID 19 telemedicine initiation flexibilities for buprenorphine for OUD. Worked on and supported HR 9886/S 5271, the Broadening Utilization of Proven and Effective Treatment for Recovery Act or the BUPE for Recovery Act, which would require the Administrator of the Drug Enforcement Administration (DEA) to temporarily exempt buprenorphine from the Suspicious Orders Report System (SORS) for the remainder of the opioid public health emergency. Joined coalition letter urging passage of the Connecting Our Medical Providers with Links to Expand Tailored and Effective (COMPLETE) Care Act (H.R. 5819/S.1378), which would encourage the adoption of integrated delivery models that will make behavioral health services more accessible to patients. It would do this through a temporary increase in Medicare reimbursement rates for integrated care codes. ASAM joined over 60 organization signatories in a letter to the Centers for Medicare and Medicaid Services (CMS) regarding proposed guidance and templates for parity compliance in Medicaid and the Children's Health Insurance Program (CHIP). Joined coalition letter encouraging CMS to strengthen the Medicaid parity regulations by aligning them with parity regulations recently finalized for commercial plans. The letter also recommended that CMS amend the templates and guidance documents to more closely align with the federal parity statute and regulations. Joined coalition letter requesting that Congress pass legislation to both prevent the scheduled 2.83 percent Medicare physician payment cut and, critically, provide a positive payment update for 2025.

Advocated for increased FY25 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY25 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for passage of H.R. 7050 - the Substance Use Disorder Workforce Act of 2024, with a recommendation that the Senate include additional monetary incentives in the bill for physicians training as addiction specialists. Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for the Residential Recovery for Seniors Act (H.R. 9232 / S. 4860). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for various substance use disorder workforce and coverage policy changes, including the SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. Supported the Medicaid Bump Act of 2024 (H.R. 4892/S. 3921). This legislation would incentivize states to expand coverage of mental health and substance use disorder (MH/SUD) services by providing a corresponding increase in the Federal Medical Assistance Percentage (FMAP) matching rate to 90 percent. Supported calls for the Biden Administration to rescind a $75 'cap' per patient per budget year on incentives in contingency management for treating stimulant use disorder. Advocated for the finalization of a DOJ/DEA rule to preserve the COVID 19 telemedicine initiation flexibilities for buprenorphine for OUD. Worked on and supported HR 9886/S 5271, the Broadening Utilization of Proven and Effective Treatment for Recovery Act or the BUPE for Recovery Act, which would require the Administrator of the Drug Enforcement Administration (DEA) to temporarily exempt buprenorphine from the Suspicious Orders Report System (SORS) for the remainder of the opioid public health emergency. Joined coalition letter urging passage of the Connecting Our Medical Providers with Links to Expand Tailored and Effective (COMPLETE) Care Act (H.R. 5819/S.1378), which would encourage the adoption of integrated delivery models that will make behavioral health services more accessible to patients. It would do this through a temporary increase in Medicare reimbursement rates for integrated care codes. ASAM joined over 60 organization signatories in a letter to the Centers for Medicare and Medicaid Services (CMS) regarding proposed guidance and templates for parity compliance in Medicaid and the Children's Health Insurance Program (CHIP). Joined coalition letter encouraging CMS to strengthen the Medicaid parity regulations by aligning them with parity regulations recently finalized for commercial plans. The letter also recommended that CMS amend the templates and guidance documents to more closely align with the federal parity statute and regulations. Joined coalition letter requesting that Congress pass legislation to both prevent the scheduled 2.83 percent Medicare physician payment cut and, critically, provide a positive payment update for 2025.

Abortion access (general); Access to mifepristone (general); Contraception (general); IUD insertion (general); Maternal mortality and morbidity (general); H.R. 1117, Advancing Safe Medications for Moms and Babies Act; Inclusion of pregnant and lactating individuals in research (general); Obstetric and gynecologic care in rural and underserved areas (general); impact of closures of ob-gyn units in rural hospitals on patient access to care and maternal morbidity and mortality; Impact of abortion restrictions on patient outcomes and the ob-gyn workforce (general); H.R. 3305/S. 1606, Black Maternal Health Momnibus Act; H.R. 3310/S. 2239, Kira Johnson Act; H.R. 3312/S. 1602, Moms Matter Act; H.R. 3320/S. 1599, Data to Save Moms Act; H.R. 3523/S. 1710, Perinatal Workforce Act;; H.R. 2389/S. 1302, Resident Physician Shortage Reduction Act; H.R. 2569, Doctors of Community (DOC) Act; Teaching Health Center Graduate Medication Education (general); H.R. 3838/S. 2415, Preventing Maternal Deaths Reauthorization Act of 2023; H.R. 3226/S. 1573, PREEMIE Reauthorization Act of 2023; Telemedicine (general); H.R. 5012/S. 2647, SHINE for Autumn Act; implementation of P.L. 118-69, Maternal and Child Health Stillbirth Prevention Act; Stillbirth prevention (general); S.___, Supporting Healthy Moms and Babies Act; S. 712/H.R. 8532, Connected MOM Act; S. 4079/H.R. 8383, Rural Obstetrics Readiness Act; Diversity, Equity, and Inclusion in medicine (general); S. 5236, Keep Obstetrics Local Act; H.R. 7855, H.R.___, Diane Powis Ovarian Cancer Testing Access Act;; S. 4445, Right to IVF Act; Implementation of P.L. 117-328, Pregnant Workers Fairness Act; National Health Service Corps (general); ; H.R. 8796/S. 4619, Stop Comstock Act; H.R. 8037/S. 4147, NIH Improve Act; H.R. 9886, Broadening Utilization of Proven and Effective Treatment for Recovery Act or the BUPE for Recovery Act; S. 4522, Dads Matter Act; H.R. 6716/S. 3509, Healthy MOM Act; H.R. 8839, Maternal and Infant Syphilis Prevention Act; H.R. 8223/S. 4246 Advancing Menopause Care and Mid-Life Womens Health Act; H.R. 3851/S. 2464, Access to Breast Cancer Diagnosis Act of 2023; S. 964, Mothers and Newborns Success Act; H.R. 4572/S. 2303, Stephanie Tubbs Jones Uterine Fibroid Research and Education Act of 2023; H.R. 4534/S. 2245, Women and Lung Cancer Research and Preventive Services Act of 2023; S. 3447, Pregnant and Postpartum Women Treatment Reauthorization Act; S. 3370, Promoting Maternal and Child Health Through Substance Use Prevention Act; H.R. 3946/S. 1800, FASD Respect Act; H.R. __ /S.__ Strengthening Pathways to Health Professions Act; Health Insurance Portability and Accountability Act (general); Patient-physician relationship (general); Alliance for Innovation on Maternal Health; Residency programs in obstetrics and gynecology (general); Abortion training in obstetrics and gynecology residency programs (general); Obstetrician-gynecologist workforce (general); Reproductive health data privacy (general); Substance use disorder during pregnancy (general); Maternal mental health (general); Coverage for infertility (general); Protections for in vitro fertilization (general); HPV vaccination (general); RSV vaccination (general); Remote patient monitoring (general); Fertility preservation services for sickle cell patients treated with cell and gene therapies; Prenatal supplements (general); Care for pregnant and postpartum incarcerated individuals (general); Gun violence as a public health issue (general);; H.Res.1448, Expressing the sense of the House of Representatives that every person has the basic right to emergency health care, including abortion care; CURES 2.0 Act; NIH restructuring (general); family care plans (general); FDA Advisory Committees (general); FDA Diversity Action Plan (general); NICHD Strategic Plan (general); physician liability (general); pharmacist-prescribed contraceptives (general); Task Force on Research Specific to Pregnant Women and Lactating Women (PRGLAC) recommendations (general); Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) food packages (general); Health Data, Technology, and Interoperability: Patient Engagement, Information Sharing, and Public Health Interoperability rule (general).

Fentanyl analogues scheduling extension H.R. 2584-Safety from Violence for Healthcare Employees (SAVE) Act, to establish federal criminal penalties for violence against health care workers H.R. 9886-Broadening Utilization of Proven and Effective Treatment for Recovery Act, to temporarily exempt buprenorphine from the Suspicious Orders Report System for the remainder of the opioid public health emergency S.1080-Cooper Davis Act S.2484-Expanding Nationwide Access to Test Strips Act, to ensure states do not prohibit individuals from possessing or obtaining fentanyl test strips S.2644-American Law Enforcement SAVER Act, to provide standards for trauma kits purchased using Byrne JAG grant funds S.2768-Safety from Violence for Healthcare Employees (SAVE) Act, to establish federal criminal penalties for violence against health care workers S. 5271-Broadening Utilization of Proven and Effective Treatment for Recovery Act, to temporarily exempt buprenorphine from the Suspicious Orders Report System for the remainder of the opioid public health

Client expense: $428,634 · Firm income: Not reported

S. 2666, the E-Prescribing Parity for Controlled Substances Act; Remote Prescribing of Controlled Substances & Dispensing of Controlled Substances; H.R. 9886, the BUPE for Recovery Act;

Client expense: $380,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Increasing access to mental health and substance use treatment Mental health & substance use disorder workforce Modernizing Opioid Treatment Access Act (H.R. 1359/S.644) Federal funding for mental health and substance use programs, research and training Make Medicare telehealth flexibilities permanent H.R. 9886/S. 5271 BUPE for Recovery Act H.R. 7635/S.5021 340B PATIENTS Act H.R. 9581 STAR Plus Scholarship Act Extend federal flexibilities for teleprescribing of controlled substances

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Advocated for increased FY25 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY25 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for at least $10.5 billion for HRSA programs in the FY 2025 Labor, Health and Human Services, Education, and Related Agencies appropriations bill. Advocated for passage of H.R. 7050 - the Substance Use Disorder Workforce Act of 2024, with a recommendation that the Senate include additional monetary incentives in the bill for physicians training as addiction specialists. Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for the Residential Recovery for Seniors Act (H.R. 9232 / S. 4860). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for various substance use disorder workforce and coverage policy changes, including the SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. Supported the Medicaid Bump Act of 2024 (H.R. 4892/S. 3921). This legislation would incentivize states to expand coverage of mental health and substance use disorder (MH/SUD) services by providing a corresponding increase in the Federal Medical Assistance Percentage (FMAP) matching rate to 90 percent. Supported calls for the Biden Administration to rescind a $75 'cap' per patient per budget year on incentives in contingency management for treating stimulant use disorder. Advocated for the finalization of a DOJ/DEA rule to preserve the COVID 19 telemedicine initiation flexibilities for buprenorphine for OUD. Joined coalition letter recommending that CMS finalize a proposal to narrow Medicares in-custody definition to no longer include individuals on bail, parole, probation, and home detention. Joined coalition letter expressing support of proposed CMS actions to address Conditions of Participation for hospitals and critical access hospitals (CAHs) to improve maternal health outcomes. The letter requested that CMS expand the proposals to include substance use-related maternal health needs, recognizing that overdose is now a leading cause of maternal mortality. Submitted a comment letter to the Centers for Medicare and Medicaid Services (CMS) on proposed changes to enhance access to substance use disorder (SUD) and mental health treatment. In prepared comments, ASAM recommended revisions to proposed digital mental health treatment codes, adoption of payment/coverage of intensive outpatient (IOP) treatment in standalone settings, and welcomed a proposal to allow people on bail, parole, probation, home detention, or in halfway houses to qualify for Medicare coverage. Submitted comment letter to the Drug Enforcement Administration (DEA) on a proposed rule that if finalized, would move marijuana from Schedule I of the Controlled Substances Act (CSA) to Schedule III. Worked on and supported HR 9886/S 5271, the Broadening Utilization of Proven and Effective Treatment for Recovery Act or the BUPE for Recovery Act, which would require the Administrator of the Drug Enforcement Administration (DEA) to temporarily exempt buprenorphine from the Suspicious Orders Report System (SORS) for the remainder of the opioid public health emergency.

Advocated for increased FY25 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY25 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for at least $10.5 billion for HRSA programs in the FY 2025 Labor, Health and Human Services, Education, and Related Agencies appropriations bill. Advocated for passage of H.R. 7050 - the Substance Use Disorder Workforce Act of 2024, with a recommendation that the Senate include additional monetary incentives in the bill for physicians training as addiction specialists. Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for the Residential Recovery for Seniors Act (H.R. 9232 / S. 4860). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for various substance use disorder workforce and coverage policy changes, including the SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. Supported the Medicaid Bump Act of 2024 (H.R. 4892/S. 3921). This legislation would incentivize states to expand coverage of mental health and substance use disorder (MH/SUD) services by providing a corresponding increase in the Federal Medical Assistance Percentage (FMAP) matching rate to 90 percent. Supported calls for the Biden Administration to rescind a $75 'cap' per patient per budget year on incentives in contingency management for treating stimulant use disorder. Advocated for the finalization of a DOJ/DEA rule to preserve the COVID 19 telemedicine initiation flexibilities for buprenorphine for OUD. Joined coalition letter recommending that CMS finalize a proposal to narrow Medicares in-custody definition to no longer include individuals on bail, parole, probation, and home detention. Joined coalition letter expressing support of proposed CMS actions to address Conditions of Participation for hospitals and critical access hospitals (CAHs) to improve maternal health outcomes. The letter requested that CMS expand the proposals to include substance use-related maternal health needs, recognizing that overdose is now a leading cause of maternal mortality. Submitted a comment letter to the Centers for Medicare and Medicaid Services (CMS) on proposed changes to enhance access to substance use disorder (SUD) and mental health treatment. In prepared comments, ASAM recommended revisions to proposed digital mental health treatment codes, adoption of payment/coverage of intensive outpatient (IOP) treatment in standalone settings, and welcomed a proposal to allow people on bail, parole, probation, home detention, or in halfway houses to qualify for Medicare coverage. Submitted comment letter to the Drug Enforcement Administration (DEA) on a proposed rule that if finalized, would move marijuana from Schedule I of the Controlled Substances Act (CSA) to Schedule III. Worked on and supported HR 9886/S 5271, the Broadening Utilization of Proven and Effective Treatment for Recovery Act or the BUPE for Recovery Act, which would require the Administrator of the Drug Enforcement Administration (DEA) to temporarily exempt buprenorphine from the Suspicious Orders Report System (SORS) for the remainder of the opioid public health emergency.

Advocated for increased FY25 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY25 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for at least $10.5 billion for HRSA programs in the FY 2025 Labor, Health and Human Services, Education, and Related Agencies appropriations bill. Advocated for passage of H.R. 7050 - the Substance Use Disorder Workforce Act of 2024, with a recommendation that the Senate include additional monetary incentives in the bill for physicians training as addiction specialists. Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for the Residential Recovery for Seniors Act (H.R. 9232 / S. 4860). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for various substance use disorder workforce and coverage policy changes, including the SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. Supported the Medicaid Bump Act of 2024 (H.R. 4892/S. 3921). This legislation would incentivize states to expand coverage of mental health and substance use disorder (MH/SUD) services by providing a corresponding increase in the Federal Medical Assistance Percentage (FMAP) matching rate to 90 percent. Supported calls for the Biden Administration to rescind a $75 'cap' per patient per budget year on incentives in contingency management for treating stimulant use disorder. Advocated for the finalization of a DOJ/DEA rule to preserve the COVID 19 telemedicine initiation flexibilities for buprenorphine for OUD. Joined coalition letter recommending that CMS finalize a proposal to narrow Medicares in-custody definition to no longer include individuals on bail, parole, probation, and home detention. Joined coalition letter expressing support of proposed CMS actions to address Conditions of Participation for hospitals and critical access hospitals (CAHs) to improve maternal health outcomes. The letter requested that CMS expand the proposals to include substance use-related maternal health needs, recognizing that overdose is now a leading cause of maternal mortality. Submitted a comment letter to the Centers for Medicare and Medicaid Services (CMS) on proposed changes to enhance access to substance use disorder (SUD) and mental health treatment. In prepared comments, ASAM recommended revisions to proposed digital mental health treatment codes, adoption of payment/coverage of intensive outpatient (IOP) treatment in standalone settings, and welcomed a proposal to allow people on bail, parole, probation, home detention, or in halfway houses to qualify for Medicare coverage. Submitted comment letter to the Drug Enforcement Administration (DEA) on a proposed rule that if finalized, would move marijuana from Schedule I of the Controlled Substances Act (CSA) to Schedule III. Worked on and supported HR 9886/S 5271, the Broadening Utilization of Proven and Effective Treatment for Recovery Act or the BUPE for Recovery Act, which would require the Administrator of the Drug Enforcement Administration (DEA) to temporarily exempt buprenorphine from the Suspicious Orders Report System (SORS) for the remainder of the opioid public health emergency.

Advocated for increased FY25 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY25 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for at least $10.5 billion for HRSA programs in the FY 2025 Labor, Health and Human Services, Education, and Related Agencies appropriations bill. Advocated for passage of H.R. 7050 - the Substance Use Disorder Workforce Act of 2024, with a recommendation that the Senate include additional monetary incentives in the bill for physicians training as addiction specialists. Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for the Residential Recovery for Seniors Act (H.R. 9232 / S. 4860). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for various substance use disorder workforce and coverage policy changes, including the SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. Supported the Medicaid Bump Act of 2024 (H.R. 4892/S. 3921). This legislation would incentivize states to expand coverage of mental health and substance use disorder (MH/SUD) services by providing a corresponding increase in the Federal Medical Assistance Percentage (FMAP) matching rate to 90 percent. Supported calls for the Biden Administration to rescind a $75 'cap' per patient per budget year on incentives in contingency management for treating stimulant use disorder. Advocated for the finalization of a DOJ/DEA rule to preserve the COVID 19 telemedicine initiation flexibilities for buprenorphine for OUD. Joined coalition letter recommending that CMS finalize a proposal to narrow Medicares in-custody definition to no longer include individuals on bail, parole, probation, and home detention. Joined coalition letter expressing support of proposed CMS actions to address Conditions of Participation for hospitals and critical access hospitals (CAHs) to improve maternal health outcomes. The letter requested that CMS expand the proposals to include substance use-related maternal health needs, recognizing that overdose is now a leading cause of maternal mortality. Submitted a comment letter to the Centers for Medicare and Medicaid Services (CMS) on proposed changes to enhance access to substance use disorder (SUD) and mental health treatment. In prepared comments, ASAM recommended revisions to proposed digital mental health treatment codes, adoption of payment/coverage of intensive outpatient (IOP) treatment in standalone settings, and welcomed a proposal to allow people on bail, parole, probation, home detention, or in halfway houses to qualify for Medicare coverage. Submitted comment letter to the Drug Enforcement Administration (DEA) on a proposed rule that if finalized, would move marijuana from Schedule I of the Controlled Substances Act (CSA) to Schedule III. Worked on and supported HR 9886/S 5271, the Broadening Utilization of Proven and Effective Treatment for Recovery Act or the BUPE for Recovery Act, which would require the Administrator of the Drug Enforcement Administration (DEA) to temporarily exempt buprenorphine from the Suspicious Orders Report System (SORS) for the remainder of the opioid public health emergency.

Advocated for increased FY25 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY25 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for at least $10.5 billion for HRSA programs in the FY 2025 Labor, Health and Human Services, Education, and Related Agencies appropriations bill. Advocated for passage of H.R. 7050 - the Substance Use Disorder Workforce Act of 2024, with a recommendation that the Senate include additional monetary incentives in the bill for physicians training as addiction specialists. Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for the Residential Recovery for Seniors Act (H.R. 9232 / S. 4860). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for various substance use disorder workforce and coverage policy changes, including the SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. Supported the Medicaid Bump Act of 2024 (H.R. 4892/S. 3921). This legislation would incentivize states to expand coverage of mental health and substance use disorder (MH/SUD) services by providing a corresponding increase in the Federal Medical Assistance Percentage (FMAP) matching rate to 90 percent. Supported calls for the Biden Administration to rescind a $75 'cap' per patient per budget year on incentives in contingency management for treating stimulant use disorder. Advocated for the finalization of a DOJ/DEA rule to preserve the COVID 19 telemedicine initiation flexibilities for buprenorphine for OUD. Joined coalition letter recommending that CMS finalize a proposal to narrow Medicares in-custody definition to no longer include individuals on bail, parole, probation, and home detention. Joined coalition letter expressing support of proposed CMS actions to address Conditions of Participation for hospitals and critical access hospitals (CAHs) to improve maternal health outcomes. The letter requested that CMS expand the proposals to include substance use-related maternal health needs, recognizing that overdose is now a leading cause of maternal mortality. Submitted a comment letter to the Centers for Medicare and Medicaid Services (CMS) on proposed changes to enhance access to substance use disorder (SUD) and mental health treatment. In prepared comments, ASAM recommended revisions to proposed digital mental health treatment codes, adoption of payment/coverage of intensive outpatient (IOP) treatment in standalone settings, and welcomed a proposal to allow people on bail, parole, probation, home detention, or in halfway houses to qualify for Medicare coverage. Submitted comment letter to the Drug Enforcement Administration (DEA) on a proposed rule that if finalized, would move marijuana from Schedule I of the Controlled Substances Act (CSA) to Schedule III. Worked on and supported HR 9886/S 5271, the Broadening Utilization of Proven and Effective Treatment for Recovery Act or the BUPE for Recovery Act, which would require the Administrator of the Drug Enforcement Administration (DEA) to temporarily exempt buprenorphine from the Suspicious Orders Report System (SORS) for the remainder of the opioid public health emergency.

Advocated for increased FY25 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY25 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for at least $10.5 billion for HRSA programs in the FY 2025 Labor, Health and Human Services, Education, and Related Agencies appropriations bill. Advocated for passage of H.R. 7050 - the Substance Use Disorder Workforce Act of 2024, with a recommendation that the Senate include additional monetary incentives in the bill for physicians training as addiction specialists. Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for the Residential Recovery for Seniors Act (H.R. 9232 / S. 4860). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for various substance use disorder workforce and coverage policy changes, including the SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. Supported the Medicaid Bump Act of 2024 (H.R. 4892/S. 3921). This legislation would incentivize states to expand coverage of mental health and substance use disorder (MH/SUD) services by providing a corresponding increase in the Federal Medical Assistance Percentage (FMAP) matching rate to 90 percent. Supported calls for the Biden Administration to rescind a $75 'cap' per patient per budget year on incentives in contingency management for treating stimulant use disorder. Advocated for the finalization of a DOJ/DEA rule to preserve the COVID 19 telemedicine initiation flexibilities for buprenorphine for OUD. Joined coalition letter recommending that CMS finalize a proposal to narrow Medicares in-custody definition to no longer include individuals on bail, parole, probation, and home detention. Joined coalition letter expressing support of proposed CMS actions to address Conditions of Participation for hospitals and critical access hospitals (CAHs) to improve maternal health outcomes. The letter requested that CMS expand the proposals to include substance use-related maternal health needs, recognizing that overdose is now a leading cause of maternal mortality. Submitted a comment letter to the Centers for Medicare and Medicaid Services (CMS) on proposed changes to enhance access to substance use disorder (SUD) and mental health treatment. In prepared comments, ASAM recommended revisions to proposed digital mental health treatment codes, adoption of payment/coverage of intensive outpatient (IOP) treatment in standalone settings, and welcomed a proposal to allow people on bail, parole, probation, home detention, or in halfway houses to qualify for Medicare coverage. Submitted comment letter to the Drug Enforcement Administration (DEA) on a proposed rule that if finalized, would move marijuana from Schedule I of the Controlled Substances Act (CSA) to Schedule III. Worked on and supported HR 9886/S 5271, the Broadening Utilization of Proven and Effective Treatment for Recovery Act or the BUPE for Recovery Act, which would require the Administrator of the Drug Enforcement Administration (DEA) to temporarily exempt buprenorphine from the Suspicious Orders Report System (SORS) for the remainder of the opioid public health emergency.